{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:12:13Z","timestamp":1783177933034,"version":"3.54.6"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10637-018-0608-7","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T03:19:07Z","timestamp":1525231147000},"page":"952-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report"],"prefix":"10.1007","volume":"36","author":[{"given":"Ryosuke","family":"Hirabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3000","authenticated-orcid":false,"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Satsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hirabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"issue":"8","key":"608_CR1","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240\u20132247. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-2246","journal-title":"Clin Cancer Res"},{"issue":"7","key":"608_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, Investigators A (2017) Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"issue":"12","key":"608_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss G, Tsai C-M, Shepherd FA, Bazhenova L, Lee JS, Chang G-C, Crino L, Satouchi M, Chu Q, Hida T, Han J-Y, Juan O, Dunphy F, Nishio M, Kang J-H, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T (2016) Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology 17(12):1643\u20131652. https:\/\/doi.org\/10.1016\/s1470-2045(16)30508-3","journal-title":"The Lancet Oncology"},{"key":"608_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2017","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, Investigators F (2017) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung Cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"issue":"2","key":"608_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/mco.2017.1310","volume":"7","author":"Y Yasuda","year":"2017","unstructured":"Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, Funazo T, Nomizo T, Tsuji T, Yoshida H, Nagai H, Ozasa H, Hirai T, Kim YH (2017) Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: a case report. Mol Clin Oncol 7(2):295\u2013297. https:\/\/doi.org\/10.3892\/mco.2017.1310","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"608_CR6","first-page":"307","volume":"25","author":"J Sanchez-Lopez","year":"2015","unstructured":"Sanchez-Lopez J, Vinolas N, Munoz-Cano R, Pascal M, Reguart N, Bartra J, Valero A (2015) Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib. J Investig Allergol Clin Immunol 25(4):307\u2013308","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"11","key":"608_CR7","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1097\/JTO.0000000000000350","volume":"9","author":"MM Awad","year":"2014","unstructured":"Awad MM, Lax TP, Slawski BR, Shaw AT (2014) Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol 9(11):1726\u20131728. https:\/\/doi.org\/10.1097\/JTO.0000000000000350","journal-title":"J Thorac Oncol"},{"issue":"3","key":"608_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1046\/j.1440-1843.2003.00461.x","volume":"8","author":"JA Burrows","year":"2003","unstructured":"Burrows JA, Toon M, Bell SC (2003) Antibiotic desensitization in adults with cystic fibrosis. Respirology (Carlton, Vic) 8(3):359\u2013364","journal-title":"Respirology (Carlton, Vic)"},{"issue":"3","key":"608_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574\u2013580. https:\/\/doi.org\/10.1016\/j.jaci.2008.02.044","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"608_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/all.12161","volume":"68","author":"K Scherer","year":"2013","unstructured":"Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, Schnyder B, Whitaker P, Cernadas JS, Bircher AJ (2013) Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the drug allergy interest group. Allergy 68(7):844\u2013852. https:\/\/doi.org\/10.1111\/all.12161","journal-title":"Allergy"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0608-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:55Z","timestamp":1678559095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0608-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0608-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Ryosuke Hirabayashi declares that he has no conflict of interest. Author Daichi Fujimoto declares that he receives lecturing fee from AstraZeneca. Author Yukari Satsuma declares that she has no conflict of interest. Author Masaki Hirabatake declares that he has no conflict of interest. Author Keisuke Tomii declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}